Antonio Hernandez

Antonio Hernandez

Auto-generated profile, based on publicly available information

Antonio Hernandez

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Clinical Virology
Verified
Journal Article
Closed access
KSKinda Schepers
Kinda Schepers
AHAntonio Hernandez
Antonio Hernandez
Graciela AndreiGraciela Andrei
Graciela Andrei
SGSarah Gillemot
Sarah Gillemot
PFPierre Fiten
Pierre Fiten
RSRobert Snoeck
Robert Snoeck

4 March 2021 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
AHAntonio Hernandez
Antonio Hernandez
LNLinh T. Nguyen
Linh T. Nguyen
RDRadhika Dhakal
Radhika Dhakal
BMBrian Murphy
Brian Murphy
This viewpoint discusses limitations of sample collection and microbial strain library generation practices, and will offer suggestions to innovate these areas.

13 September 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
BPBruno S. Paulo
Bruno S. Paulo
MRMichael Joseph John Recchia
Michael Joseph John Recchia
SLSanghoon Lee
Sanghoon Lee
CFClaire H. Fergusson
Claire H. Fergusson
SRSean B. Romanowski
Sean B. Romanowski
AEAlessandra S. Eustaquio
Alessandra S. Eustaquio
Megapolipeptins show low structural similarity to known natural products, highlighting the advantage of our Burkholderiales genomics-driven and synthetic biology-enabled pipeline to discover novel natural products.

9 January 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMichael Mullowney
Michael Mullowney
AMAngelica Moran
Angelica Moran
AHAntonio Hernandez
Antonio Hernandez
MMMary McMillin
Mary McMillin
ARAmber R. Rose
Amber R. Rose
ASAshley M. Sidebottom
Ashley M. Sidebottom
The intestinal microbiome is composed of myriad microbial species with impacts on host health that are mediated by the production of metabolites. While loss of bacterial species and beneficial metabolites from the fecal microbiome is associated with development of a range of diseases and medical complications, there are currently no clinical diagnostic tests that rapidly identify individuals with microbiome deficiencies. This method aims to rapidly quantify fecal concentrations of butyrate and deoxycholic acid, as depletion of these two metabolites are associated with adverse clinical outcomes and result from the loss of a subset of health-associated bacterial species. We present a rapid diagnostic screen based on 3-nitrophenylhydrazine derivatization and ultrahigh-performance liquid chromatography-mass spectrometry that measures fecal butyrate and deoxycholic acid concentrations as markers of microbiome function. A matrix-matched calibration curve was developed using a simulated fecal mixture to optimize accuracy and facilitate adherence to clinical laboratory regulations. The assay resulted in an analytical measurement range from 4.30–3030 µM (LLOQ = 3.71 µM) for butyrate and from 0.9–64.9 µM (LLOQ = 0.7 µM) for deoxycholic acid. Precision evaluation demonstrated a coefficient of variation <15% at all quality control levels tested. The rapid liquid chromatography-mass spectrometry screen can be performed in under an hour from extraction to provision of quantitative results, enabling the rapid identification of patients with defective microbiome function.

23 July 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNyssa K. Krull
Nyssa K. Krull
MSMichael Strobel
Michael Strobel
JSJulia Saulog
Julia Saulog
LZLiana Zaroubi
Liana Zaroubi
BPBruno S. Paulo
Bruno S. Paulo
BMBrian Murphy
Brian Murphy
The identification and analysis of bacteria is central to the microbiological sciences. While gene sequencing methods have been the standard to achieve this, use of MALDI-TOF mass spectrometry (MS), particularly in clinical microbiology, can provide high-throughput identification to the subspecies level. However, biotyping has yet to be adopted outside of clinical settings due to the lack of a centralized public database of MS protein signatures that would facilitate isolate identification via spectral comparison. Further, most current MALDI MS data analysis platforms lack meaningful ways to compare properties from large numbers of bacterial isolates. Herein we present the IDBac web platform, a crowd-sourced central knowledgebase of protein MS signatures spanning seven bacterial phyla. Accompanying the knowledgebase is analysis infrastructure to identify unknown isolates, probe relationships within culture collections using metadata integration, and visualize specialized metabolite differences within groups of closely related bacteria. To highlight this utility and encourage wide community contribution, examples of each are presented.

17 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMichael Mullowney
Michael Mullowney
AMAngelica Moran
Angelica Moran
AHAntonio Hernandez
Antonio Hernandez
MMMary McMillin
Mary McMillin
ARAmber Rose
Amber Rose
ASAshley M. Sidebottom
Ashley M. Sidebottom
The intestinal microbiome is composed of myriad microbial species that produce metabolites that impact host health. While loss of bacterial species and beneficial metabolites from the fecal microbiome is associated with development of a range of diseases and medical complications, there are currently no diagnostic tests that rapidly identify individuals with microbiome deficiencies. Reduced concentrations of fecal butyrate and deoxycholic acid are associated with adverse clinical outcomes and result from the loss of a subset of health-associated bacterial species. We present a rapid diagnostic test based on 3-nitrophenylhydrazine derivatization and ultrahigh-performance liquid chromatography-mass spectrometry that measures fecal butyrate and deoxycholic acid concentrations as markers of microbiome function. A matrix-matched calibration curve was developed using a simulated fecal mixture to optimize accuracy and facilitate adherence to clinical laboratory regulations. The assay showed an analytical measurement range from 4.3–3030.1 µM (LLOQ = 9.75 µM) for butyrate and from 0.9– 64.9 µM (LLOQ = 0.9 µM) for deoxycholic acid. Precision demonstrated a coefficient of variation <15% at all QC levels tested. The assay can be performed in under an hour from extraction to provision of quantitative results, enabling the rapid identification of patients with defective microbiome function.